Clinical trials: Colorectal Carcinoma (CRC)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT07259304
- Testing
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 173 people
- Sponsor
- University of Southern California
Metastasis Colorectal Cancer
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer
- Trial name
- NCT04179084
- Testing
- fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Colorectal Cancer, Solid Tumor
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
This is a single center, open-label, nonrandomized, Phase 1b, dose-escalation study designed to determine maximum tolerated dose (MTD) of CKD-516 in combination with durvalumab and evaluate the safety and tolerability profile…
- Trial name
- NCT04696848
- Testing
- CKD-516 plus Durvalumab
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Tae Won Kim
Carcinoma, Hepatocellular, Colorectal Neoplasms
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the…
- Conditions
- Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma, Kidney Neoplasms
- Trial name
- NCT02439008
- Testing
- Blood samples collection before radiotherapy, Blood samples collection during radiotherapy, Blood samples collection after radiotherapy
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Rectal Cancer, Colorectal Cancer
Endoscopic Visualisation of Anastomosis in Colorectal Cancer Surgery
A randomised feasibility study into the use of endoscopic visualisation of rectal anastomosis vs. current practice and the effect on anastomotic leak rates in patients undergoing rectal surgery for bowel cancer in a tertiary…
- Conditions
- Rectal Cancer, Colorectal Cancer, Anastomotic Leak, Intraoperative Endoscopy
- Trial name
- EVACCS (NCT04738240)
- Testing
- Intra-operative endoscopy
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Plymouth
Colorectal Cancer
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with metastatic…
- Trial name
- NCT00003220
- Testing
- bryostatin 1
- Where
- 2 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Colorectal Cancer (CRC)
Normobaric Oxygen Therapy in Colorectal Cancer Patients
Colorectal cancer (CRC) patients undergoing chemotherapy often experience anemia, oxidative stress, and immune suppression, significantly impacting their quality of life and treatment outcomes.
- Trial name
- NBO-ONCO (NCT06946004)
- Testing
- Normobaric oxygen therapy
- Where
- Poland
- Volunteers
- 254 people
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
Colorectal Neoplasms, Organoids
Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs
The individualized treatment of tumors has always been an urgent problem in clinical practice. Organoids-on-a-chip can reflect the heterogeneity of tumors and is a good model for in vitro anticancer drug screening.
- Trial name
- NCT04996355
- Testing
- comprehensive treatment after MDT discussion
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University People's Hospital
Cancer, Tyrosine Kinase Mutation
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the…
- Conditions
- Cancer, Tyrosine Kinase Mutation, Breast Cancer, Melanoma
- Trial name
- LONGEVITI (NCT05645510)
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University of Alberta
Metastatic Colorectal Cancer
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Molecular subtypes make difference on clinicopathologic features and response to chemotherapy and targeted agents as well as prognosis.
- Trial name
- NCT05522738
- Testing
- Combination: Fruquintinib + FOLFIRI
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Chinese PLA General Hospital
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Melanoma, Lung Cancer, or Colorectal Cancer
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues.
- Trial name
- NCT05190185
- Testing
- TAA06 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Advanced Colorectal Cancer
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.
- Trial name
- NCT04324476
- Testing
- Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Colorectal Cancer
Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer.
3rd line standard treatment of patients with metastatic colorectal cancer (CRC) harboring K-ras wild type consists of anti-EGFR treatment with either cetuximab or panitumumab.
- Trial name
- NCT01691391
- Testing
- (Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer
Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy
Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. The death rate from this disease, however, has been decreasing over the last 20 years.
- Trial name
- NCT02621658
- Testing
- Clear Liquid Diet, Full Liquid Diet
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- San Antonio Military Medical Center
Colon Cancer, Rectal Cancer
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery.
- Trial name
- NCT01363843
- Testing
- FOLFOX6, RT with concurrent chemotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- William Sikov MD
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT05627635
- Testing
- Balstilimab, Bevacizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Colorectal Carcinoma
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high (MSI-H) or DNA mismatch…
- Trial name
- NCT04988191
- Testing
- Toripalimab, Bevacizumab, Irinotecan
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Peking University
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.